NDAORALCAPSULE, EXTENDED RELEASE
Approved
Mar 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ISOCLOR (chlorpheniramine maleate; pseudoephedrine hydrochloride) by Ascentage Pharma. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications. First approved in 1986.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOCLOR is an oral extended-release capsule combining chlorpheniramine maleate (antihistamine) and pseudoephedrine hydrochloride (decongestant) for symptomatic relief of hay fever and upper respiratory allergies. It targets nasal congestion, runny nose, sneezing, and itching by blocking histamine receptors and stimulating sympathomimetic vasoconstriction. The combination formulation addresses multiple allergy symptoms in a single dosing regimen.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential contraction in brand team investment and shift toward defensive positioning or brand rationalization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ISOCLOR at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.